ATLAS: A phase 2, open-label study of rucaparib in patients (pts) with locally advanced or metastatic urothelial carcinoma (mUC)

Autor:	Simon Chowdhury, Yohann Loriot, Petros Grivas, Daleen Thomas, Yousef Zakharia, Susan Feyerabend, Alejo Rodriguez-Vida, Rachel L. Dusek, Andrea Necchi, Andrew Simmons, Dale L. Nepert, Sumati Gupta, Ajjai Alva, Sandy Srinivas, Nicholas J. Vogelzang, Kenton Wride, Debra H. Josephs
Rok vydání:	2018
Předmět:	0301 basic medicine Cancer Research Metastatic Urothelial Carcinoma endocrine system diseases Immune checkpoint inhibitors medicine.medical_treatment Locally advanced macromolecular substances 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Open label study otorhinolaryngologic diseases Medicine In patient Rucaparib Chemotherapy business.industry Treatment options 030104 developmental biology Oncology chemistry 030220 oncology & carcinogenesis Cancer research bacteria business hormones hormone substitutes and hormone antagonists
Zdroj:	Journal of Clinical Oncology. 36:TPS4592-TPS4592
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2018.36.15_suppl.tps4592
Popis:	TPS4592Background: There are limited treatment options for pts with mUC that has progressed during or after platinum-based chemotherapy and/or immune checkpoint inhibitors (ICIs), emphasizing the n...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::4e3db8f6e19878df2b6c96395061f877 https://doi.org/10.1200/jco.2018.36.15_suppl.tps4592 Zobrazit plný text záznamu